Trial Profile

A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Skin cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms STARBOARD
Sponsors Pfizer

03 Sep 2026 Planned End Date changed from 31 Aug 2026 to 30 Oct 2026.
03 Sep 2026 Actual primary completion date changed from 12 Jan 2026 to NULL.
03 Sep 2026 Planned primary completion date changed from 14 Dec 2025 to 30 Oct 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com